Delta 9 Cannabis, a Manitoba-based medical marijuana producer, has entered into a deal with a U.S. company for the rights to a technology that allows medicine to be administered through the skin or mucous membrane.

This nano technology was produced by the startup Nanosphere Health Sciences. It allows for medicines to go directly into the bloodstream, which stops it from going through the gut or the liver.

According to a news release from Delta 9, in terms of cannabis this means someone “can get better ‘bio-availability’ of cannabinoids than even smoking provides.” The company adds that it is the first technology that provides a dosage system for cannabis that is medically appropriate.

According to some studies, CBD isn’t the only cannabinoid that can help sick children.

The results of two recent studies suggest that THC may be effective in treating epilepsy. The news comes amid numerous reports that another cannabinoid, cannabidiol (CBD), may also be a viable treatment for seizure disorders. The work of medical researchers in Canada and Australia may indicate that cannabis medications with a combination of cannabinoidsmay be more effective at reducing seizures than CBD alone.

Medical marijuana producer Aphria Inc. says its revenues surged in the fourth quarter of its fiscal year but its net loss nearly doubled as it expands in preparation for Canada legalizing recreational cannabis use in October.

The Leamington, Ont.-based company's net loss nearly doubled to $5 million from $2.6 million in the prior year on higher compensation, costs associated with Aphria International and losses in its investment portfolio, partially offset by increased gross profit.

The company has been busy raising money and making acquisition deals, including its February purchase of B.C.-based Broken Coast Cannabis Inc., a transaction valued at more than $200-million in stock and cash.

The buzz around Canada’s legal marijuana market has turned Ottawa’s National Access Cannabis (TSX-V:META) into a “bees’ nest of activity” – and the prospect of private pot retail in Ontario is only sweetening the local firm’s honeypot.

As Canada counts down to the legalization of recreational cannabis on Oct. 17, Canadian Kush Tours is busy hiring guides.

Owner Neev Tapiero, who hosted his first paying customers six months ago, said he expects an “explosion” of visitor interest in Toronto’s cannabis scene, especially among Americans.

“By this time next year I want to offer daily walking tours from hotspots like Dundas Square and Union Station,” Tapiero said while sitting in Vapor Central, one of seven downtown vapour lounges and dispensaries that Kush visits by limousine or bus. “We’re focusing not just on tourists coming specifically to smoke cannabis, but also on those who may not know you can smoke it legally in Canada.”

A cannabis compound that won't get users high can help ease the nausea cancer patients experience when going through chemotherapy, a new University of Guelph study suggests.

One of the first medical uses of THC (tetrahydrocannabionl), the psychoactive compound in cannabis that results in a person becoming high, was to treat chemotherapy-induced nausea and vomiting.

This study shows alternate compounds of the cannabis plant could be used and are just as, or more effective, than other drugs used for nausea.

Strainprint Technologies Ltd. (Strainprint™) – the leader in cannabis strain data and analytics – is excited to announce the addition of two key senior team members: Michelle Arbus, Vice President of Research & Insights, and Noah Kauffman, Director of Sales.  

With cannabis legalization just around the corner, one Canadian company is calling for the inclusion of cannabis concentrates in Bill C-45, the so-called “Cannabis Act.”

Josh Campbell, president of cannabis company Dosist Canada, says in omitting concentrates from legalization, consumers are being denied a method for consistent delivery of THC and CBD — the two most commonly sought-after drugs contained in the cannabis plant.

“When we talk about dose, we’re talking about a controlled, repeatable experience,” Campbell told StarMetro in an email. “Without that. you lose predictability and control – the cornerstones of a safe and therapeutic experience. Dose control is critical for responsible use.”

NanoSphere Health Sciences, Inc, the biotechnology leader behind the patented NanoSphere Delivery System, has entered into a partnership with Delta 9 Cannabis INC to bring products from its cannabis brand, Evolve Formulas, into the Canadian market.

Recently awarded U.S. Patent No. 10,028,919, NanoSphere has just been granted market exclusivity over the standardized delivery of cannabis into systemic circulation through phospholipid nanoparticle technology. The new patent complements NanoSphere’s previously issued patent, U.S. Patent No. 9,925,149, covering the core technology behind the production of the NanoSphere Delivery System.

Many Canadian companies have entered into partnerships, joint ventures, and other agreements to expand their business footprint in anticipation of the October 17 date when nationwide legalization goes into full swing. Village Farms International, Inc. (TSX:VFF) (OTC:VFFIF) and Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) are no different and have formed a 50/50 joint venture called Pure Sunfarms, for large-scale cannabis production.